KR840005725A - 융합 4h-1,4-벤조티아진의 제조방법 - Google Patents

융합 4h-1,4-벤조티아진의 제조방법 Download PDF

Info

Publication number
KR840005725A
KR840005725A KR1019830003619A KR830003619A KR840005725A KR 840005725 A KR840005725 A KR 840005725A KR 1019830003619 A KR1019830003619 A KR 1019830003619A KR 830003619 A KR830003619 A KR 830003619A KR 840005725 A KR840005725 A KR 840005725A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
alkoxy
optionally substituted
compound
Prior art date
Application number
KR1019830003619A
Other languages
English (en)
Inventor
니머 엑케하르드 (외 4)
Original Assignee
칼-루드빅 쉬미트, 귄터 슈마허
바이엘 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼-루드빅 쉬미트, 귄터 슈마허, 바이엘 아크티엔 게젤샤프트 filed Critical 칼-루드빅 쉬미트, 귄터 슈마허
Publication of KR840005725A publication Critical patent/KR840005725A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

내용 없음

Description

융합 4H-1,4- 벤조티아진의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음 일반식(Ⅱ)의 2-아미노티오페놀과 다음 일반식(Ⅲ)의 화합물을 디메틸술폭사이드내에서 반응시켜 다음 일반식(Ⅰ)의 화합물을 제조함을 특징으로 한 융합 4 H-1,4- 벤조티아진의 제조방법.
  3. 상기 일반식에서, R1은 수소 및 임의로 치환된 알킬을 나타내며, R2와 R3는 수소, 임의로 치환된 알킬, 할로겐, 니트로, 시아노, 알킬술포닐, 히드록실, 알콕시 또는 아실옥시(R2또는 R3가 브롬을 나타내지 않거나 또는 R2또는 R3둘다가 수소를 나타내지 않는 조건하에서 R2와 R3는 서로 동일하거나 다를 수 있다)를 나타내며, X는 알킬, 알콕시, 아릴, 플루오르 또는 알콕시카보닐 등에 의해 한번 또는 여러번 치환될 수 있는 알킬렌(2 내지 4개의 탄소원자를 가지고 있다)을 나타내며 또한 알킬렌 브리지의 메틸렌 그룹이 O, S, SO2, SO, NH 또는 N-알킬로 치환될 수 있다.
  4. 임의로 촉매량의 산을 사용하여, 다음 일반식(Ⅲ)의 디카보닐 화합물과 다음 일반식(Ⅳ)의 디술파이드를 반응시켜 다음 일반식(Ⅰ)의 화합물을 제조함을 특징으로한 융합 4H-1,4- 벤조티아진의 제조방법.
  6. 상기 일반식에서, R1은 수소 및 임의로 치환된 알킬을 나타내며, R2와 R3는 수소, 임의로 치환된 알킬할로겐, 니트로, 시아노, 알킬술포닐, 아릴술포닐, 히드록실, 알콕시 또는 아실옥시(R2또는 R3가 브롬을 나타내지 않거나 또는 R2와 R3둘다가 수소를 나타내지 않는 조건하에서 R2와 R3는 서로 동일하거나 다를 수 있다)를 나타내며, X는 알킬, 알콕시, 아릴, 플루오르 또는 알콕시카보닐등에 의해 한번 또는 여러번 치환될 수 있는 알킬렌(2 내지 4개의 탄소원자를 가지고 있다)을 나타내며 또한 알킬렌 브리지의 메틸렌 그룹이 O, S, SO2, SO, NH 또는 N-알킬로 치환될 수 있다.
  7. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830003619A 1982-08-04 1983-08-02 융합 4h-1,4-벤조티아진의 제조방법 KR840005725A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3229122,1 1982-08-04
DE19823229122 DE3229122A1 (de) 1982-08-04 1982-08-04 Anellierte 4h-1,4-benzothiazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
KR840005725A true KR840005725A (ko) 1984-11-16

Family

ID=6170117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830003619A KR840005725A (ko) 1982-08-04 1983-08-02 융합 4h-1,4-벤조티아진의 제조방법

Country Status (16)

Country Link
US (1) US4636497A (ko)
EP (1) EP0101898A1 (ko)
JP (1) JPS5944370A (ko)
KR (1) KR840005725A (ko)
AU (1) AU1741483A (ko)
DE (1) DE3229122A1 (ko)
DK (1) DK354583A (ko)
ES (1) ES524713A0 (ko)
FI (1) FI832784A (ko)
GR (1) GR79355B (ko)
HU (1) HU189314B (ko)
IL (1) IL69388A0 (ko)
NO (1) NO832625L (ko)
PH (1) PH18784A (ko)
PT (1) PT77097B (ko)
ZA (1) ZA835673B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138481B1 (en) * 1983-10-05 1991-06-26 Merck Frosst Canada Inc. Leukotriene biosynthesis inhibitors
EP0149297B1 (en) * 1983-12-27 1987-11-25 Merck Frosst Canada Inc. Process for preparing 3h-phenothlazin-3-ones
EP0155623A3 (en) * 1984-03-19 1985-12-27 Merck & Co. Inc. Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition
US4500708A (en) * 1984-04-23 1985-02-19 G. D. Serle & Co. Benzothiazine derivatives
DE3426564A1 (de) * 1984-07-19 1986-01-30 Bayer Ag, 5090 Leverkusen Verwendung von 4h-1,4-benzothiazinen bei der prophylaxe und therapie von erkrankungen der atemwege, entzuendungen/rheuma, thromboembolischen erkrankungen, ischaemien und infarkten, herzrhythmusstoerungen, arteriosklerose und dermatosen, arzneimittel zu diesem zweck sowie wirkstoffe, die in diesen arzneimitteln enthalten sind
DE3540702A1 (de) * 1985-11-16 1987-05-21 Bayer Ag 1h-pyrido-(2,3-b) (1,4)-thiazine
DE3545097A1 (de) * 1985-12-19 1987-07-02 Bayer Ag 1-h-pyrido-(3,2-b)(1,4)-thiazine
US4921838A (en) * 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
US5981294A (en) * 1995-11-29 1999-11-09 Metrika, Inc. Device for blood separation in a diagnostic device
US5994349A (en) * 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1088055B (de) * 1958-05-16 1960-09-01 Chem Fab Promonta Ges Mit Besc Verfahren zur Herstellung von Hexahydrophenthiazin-9-dioxyden
DE1151802B (de) * 1960-04-28 1963-07-25 Chem Fab Promonta Ges Mit Besc Verfahren zur Herstellung von cycloalkylierten 2,3-Dihydro-1,4-benzthiazinen
US3422101A (en) * 1967-05-05 1969-01-14 Mcneilab Inc Tetrahydrothienobenzothiazines
US4512990A (en) * 1982-02-18 1985-04-23 Syntex (U.S.A.), Inc. Benzthiazine analogs as antiinflammatory agents

Also Published As

Publication number Publication date
HU189314B (en) 1986-06-30
JPS5944370A (ja) 1984-03-12
FI832784A (fi) 1984-02-05
ES8404607A1 (es) 1984-05-01
GR79355B (ko) 1984-10-22
ZA835673B (en) 1984-04-25
PT77097A (en) 1983-08-01
NO832625L (no) 1984-02-06
PT77097B (en) 1986-03-12
DE3229122A1 (de) 1984-02-09
ES524713A0 (es) 1984-05-01
IL69388A0 (en) 1983-11-30
DK354583A (da) 1984-02-05
US4636497A (en) 1987-01-13
EP0101898A1 (de) 1984-03-07
FI832784A0 (fi) 1983-08-02
PH18784A (en) 1985-09-25
DK354583D0 (da) 1983-08-03
AU1741483A (en) 1984-02-09

Similar Documents

Publication Publication Date Title
KR840004406A (ko) 히단토인의 제조방법
KR860001793A (ko) 벤즈 이미다졸 유도체의 제조방법
KR850007254A (ko) 니트로메틸렌 유도체의 제조방법
KR840008016A (ko) 융합 이미다졸 화합물의 제조방법
KR840004441A (ko) 포스포리피드 유도체의 제조방법
KR840005725A (ko) 융합 4h-1,4-벤조티아진의 제조방법
KR830007686A (ko) 세팔로 스포린 유도체의 제조방법
KR840006324A (ko) 2-니트로-1,1-에렌디아민의 제조방법
KR840009104A (ko) 2'-데옥시-5-치환우리딘 유도체의 제조방법
KR860008166A (ko) 카바모일이미다졸의 제조방법
KR860001097A (ko) 4-아미노-2-페닐퀴놀린의 제조방법
KR860004037A (ko) 페닐하이드라진의 제조방법
KR840006234A (ko) 1,3-디티안류의 제조방법
KR850008159A (ko) 2-페닐-4,5,6,7-테트라히드로-2h-인다졸류의 제조방법
KR850004470A (ko) 유기 화합물의 제조방법
KR860002474A (ko) 치환된 페닐술포닐아졸의 제조방법
KR840005727A (ko) 4h-1,4- 벤조티아진의 제조방법
KR840004093A (ko) 3,4-디하이드로-2h-1,2-벤조티아진-카복실산-1,1-디옥사이드류의 제조방법
KR840002349A (ko) 카바모 일-옥심의 제조
KR840000496A (ko) 요소유도체 및 그 제조방법
KR870007908A (ko) 인덴류 화합물의 제조방법
KR840005441A (ko) 헥사히드로디옥소피리미딘류의 제조방법
KR870008840A (ko) 1-스티렌술포닐-2-옥소-5-히드록시 피롤리딘 유도체의 제조방법
KR860007333A (ko) 모노아조화합물의 제조방법
KR830010096A (ko) 자일라이트 유도체의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid